Precigen Achieves First Profitable Quarter with Strong Papzimeos Sales
PGEN has more than doubled off its 52-week low of $1.7.
Summary
Precigen reported its first profitable quarter in Q2 2026 with $20.1 million in net income, fueled by $53.1 million in Papzimeos sales, marking a significant milestone in its commercialization efforts.
Key Events · Earnings and Guidance · PGEN
-
First Profitable Quarter Since 2020
Precigen reported Q2 2026 net income of $20.1 million, or $0.05 diluted EPS, a substantial improvement from a net loss of $(26.6) million in Q2 2025. This marks the company's first profitable quarter since its strategic transformation in 2020.
-
Massive Revenue Growth Driven by Papzimeos
Total revenues surged to $55.0 million in Q2 2026, up from $0.9 million in Q2 2025. This growth was primarily driven by $53.1 million in net product revenue from Papzimeos, following its FDA approval in August 2025.
-
Increased Operating Cash Burn for Commercial Launch
Net cash used in operating activities increased to $(61.6) million for the first six months of 2026, compared to $(35.3) million in the prior year. This was primarily due to increases in accounts receivable and inventory as the company ramps up commercial sales of Papzimeos.
-
CEO 10b5-1 Plan Modified
CEO Helen Sabzevari modified her Rule 10b5-1 trading arrangement on June 30, 2026, to revise pricing terms for future sales. The remaining shares subject to sale under this pre-planned arrangement are 130,424.
Analysis · PGEN · Life Sciences
This 10-Q filing confirms a significant turnaround for Precigen, reporting its first profitable quarter since 2020, driven by robust commercial sales of its newly approved drug, Papzimeos. While operating cash burn increased due to the commercial launch and inventory build-up, the overall financial performance indicates successful product commercialization and a positive shift in the company's trajectory. The market had some prior indication from news reports, but this filing provides the official, detailed financial results.
At the time of this filing, PGEN was trading at $7.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.70 to $6.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.